ALS Ltd's stock soared 5.08% during Tuesday's intraday trading session, driven by positive analyst commentary and upgraded earnings estimates following the company's strong financial performance.

The surge comes after multiple brokerages raised their outlook on the lab-testing group. Jefferies lifted its price target for ALS by 6.1% to A$24.40 per share, noting scope for stronger revenue and margin expansion from fiscal year 2028 onward, partly reflecting AI and automation initiatives. The brokerage also highlighted that activity among junior miners is picking up and that ALS should get a full-year contribution from its new Sydney and Lima laboratories.

Furthermore, analysts pointed to a positive commodity price environment in gold and copper that should continue to support exploration spending, with Morgans stating that the company's commodities guidance appears conservative and that underlying data suggests volumes should be accelerating. These factors, combined with ALS's reported 24.4% jump in FY26 net profit, have fueled investor optimism and contributed to the stock's significant intraday gain.